Treatment outcomes for patients with metastatic castrate‐resistant prostate cancer following docetaxel for hormone‐sensitive disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment outcomes for patients with metastatic castrate‐resistant prostate cancer following docetaxel for hormone‐sensitive disease

Published:2020-09-24 Issue:1 Volume:17 Page:36-42
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Schmidt Andrew¹²^ORCID,Anton Angelyn³⁴,Shapiro Julia⁵,Wong Shirley⁶,Azad Arun⁵⁷,Kwan Edmond⁵⁸,Spain Lavinia⁴⁵,Muthusamy Arun¹,Torres Javier⁹,Parente Phillip⁴⁵,Parnis Francis¹⁰¹¹,Goh Jeffrey¹²,Joshua Anthony M.¹³,Pook David⁵,Gibbs Peter³⁶,Tran Ben³⁷,Weickhardt Andrew¹

Affiliation:

1. Olivia Newton‐John Cancer Wellness and Research Centre Melbourne Australia

2. Dana Farber Cancer Institute Boston MA USA

3. Walter and Eliza Hall Institute Melbourne Australia

4. Eastern Health Melbourne Australia

5. Monash University Melbourne Australia

6. Western Health Melbourne Australia

7. Peter MacCallum Cancer Centre

8. Monash Health

9. Goulburn Valley Health Shepparton Australia

10. Adelaide Cancer Centre Adelaide Australia

11. University of Adelaide Adelaide Australia

12. Royal Brisbane and Women's Hospital Brisbane Australia

13. St Vincent's Hospital Sydney Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13447

Reference24 articles.

1. STUDIES ON PROSTATIC CANCER

2. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

3. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

4. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

5. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review;Future Oncology;2023-11

2. UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer;Urologic Oncology: Seminars and Original Investigations;2022-12

3. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial;European Journal of Cancer;2022-09

4. Beyond standard data collection – the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry);BMC Cancer;2022-06-02

5. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer;Bioengineered;2021-01-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3